临床特征联合外周血血管内皮生长因子和α-羟基丁酸脱氢酶对卵巢癌的诊断价值

doi:10. 20223 / j. cnki. 1000-8535. 2026. 01. 011

摘要/Abstract

摘要： 目的探讨临床特征联合外周血血管内皮生长因子（VEGF）与α-羟基丁酸脱氢酶（α-HBDH）对卵巢癌的诊断价值。方法选取2022年6月—2024年6月在天津市中心妇产科医院妇科接收的84例卵巢癌恶性肿瘤患者纳入观察组,同期选取84例卵巢良性病变患者纳入对照组。对比两组患者临床资料及VEGF、α-HBDH水平的差异,分析VEGF、α-HBDH水平与卵巢癌恶性肿瘤患者临床特征的相关性。采用二元Logistics回归分析卵巢癌恶性肿瘤的独立危险因素,并采用受试者工作特征（ROC）曲线分析VEGF、α-HBDH水平诊断卵巢癌恶性肿瘤的价值。结果观察组年龄、身体质量指数（BMI）及血清CA125、HE4、VEGF、α-HBDH水平显著高于对照组（P<0.05）,VEGF与α-HBDH水平与国际妇产科联盟（FIGO）分期、分化等级及淋巴结转移均呈正相关关系（P<0.05）。将年龄、BMI、VEGF、α-HBDH作为自变量纳入二元Logistic回归,结果显示BMI、VEGF、α-HBDH是卵巢癌恶性肿瘤的影响因素（P<0.05）,ROC曲线分析显示,联合检测VEGF和α-HBDH的AUC达0.921,灵敏度和特异度分别为81.0%和91.7%,优于单独检测（VEGF：AUC=0.702;α-HBDH：AUC=0.796）。结论 BMI联合VEGF与α-HBDH检测可为卵巢癌的诊断提供高效、无创的辅助手段,具有重要临床应用潜力。

关键词: 临床特征, 血管内皮生长因子, α-羟基丁酸脱氢酶, 卵巢癌, 诊断

Abstract: Objective To explore the diagnostic value of clinical features combined with peripheral blood vascular endothelial growth factor（VEGF）and α-hydroxybutyrate dehydrogenase（α-HBDH）levels in ovarian cancer. Methods A total of 84 patients with malignant ovarian cancer admitted to the gynecology department of Tianjin Central Hospital of Gynecology and Obstetrics from June 2022 to June 2024 were included in the observation group,and 84 patients with benign ovarian lesions during the same period were included in the control group.The clinical data and VEGF,α-HBDH levels of the two groups were compared. Pearson analysis was used to explore the correlation between VEGF,α-HBDH levels,and clinical characteristics of patients with malignant ovarian cancer.Binary Logistic regression analysis was conducted to identify independent risk factors for malignant ovarian cancer,and receiver operating characteristic（ROC） curves were used to analyze the diagnostic value of VEGF and α-HBDH levels for malignant ovarian cancer. Results The observation group had significantly higher age,BMI,and serum CA125,HE4,VEGF,α-HBDH levels compared to the control group（P<0.05）.VEGF and α-HBDH levels were significantly positively correlated with FIGO stage,differentiation grade,and lymph node metastasis（P<0.05）.Age,BMI,VEGF,and α-HBDH were included as independent variables in binary Logistic regression,and the results showed that BMI,VEGF,and α-HBDH levels were independent risk factors for malignant ovarian cancer（P<0.05）.ROC curve analysis revealed that the AUC for combined detection of VEGF and α-HBDH reached 0.921,with sensitivity and specificity of 81.0% and 91.7%,respectively,significantly superior to individual detection（VEGF：AUC=0.702;α-HBDH：AUC=0.796）. Conclusions The detection of BMI combined with VEGF and α-HBDH levels can provide an efficient and noninvasive auxiliary means for the diagnosis of ovarian cancer,which has important clinical application potential.

Key words: clinical features, vascular endothelial growth factor, α-hydroxybutyrate dehydrogenase, ovarian cancer, diagnosis

张琼文, 于天舒, 张姗, 杨富涵. 临床特征联合外周血血管内皮生长因子和α-羟基丁酸脱氢酶对卵巢癌的诊断价值[J]. 广州医药, 2026, 57(1): 77-82.

ZHANG Qiongwen, YU Tianshu, ZHANG Shan, YANG Fuhan. Diagnostic value of clinical features combined with peripheral blood vascular endothelial growth factor and α-hydroxybutyrate dehydrogenase levels in ovarian cancer[J]. Guangzhou Medical Journal, 2026, 57(1): 77-82.

参考文献

[1] 国家癌症中心,国家肿瘤质控中心卵巢癌质控专家委员会.中国卵巢癌规范诊疗质量控制指标(2022版)[J].中华肿瘤杂志,2022,44(7):609-614.
[2] GAONA-LUVIANO P,MEDINA-GAONA L A,MAGAÑA-PÉREZ K.Epidemiology of ovarian cancer[J].Chin Clin Oncol,2020,9(4):47.
[3] ZHANG M,CHENG S,JIN Y,et al.Roles of CA125 in diagnosis,prediction,and oncogenesis of ovarian cancer[J].Biochim Biophys Acta Rev Cancer,2021,1875(2):188503.
[4] MARYAM N,AHMED S S,ALAM R,et al.Role of serum VEGF-A biomarker for early diagnosis of ovarian cancer instead of CA-125[J].J Pak Med Assoc,2021,71(9):2192-2197.
[5] HE Y,OUYANG Z,LIU W,et al.TARDBP promotes ovarian cancer progression by altering vascular endothelial growth factor splicing[J].Oncogene,2023,42(1):49-61.
[6] ZHAN C H,LIU G J.Diagnostic value of a combined serum α-hydroxybutyrate dehydrogenase,carcinoembryonic antigen and glycoantigen 125 test for early-stage breast cancer[J].Breast Cancer(Dove Med Press),2023(15):617-623.
[7] 中国抗癌协会妇科肿瘤专业委员会.卵巢恶性肿瘤诊断与治疗指南(2021年版)[J].中国癌症杂志,2021,31(6):490-500.
[8] 王晓君,刘军秀.人工智能在妇科恶性肿瘤中的进展[J].中山大学学报(医学科学版),2025,46(1):21-29.
[9] 中国医师协会妇产科医师分会妇科肿瘤学组,中国医师协会微无创医学专业委员会妇科肿瘤学组,张国楠,等.卵巢透明细胞癌临床诊治指南(2024年版)[J].中国实用妇科与产科杂志,2024,40(12):1204-1216.
[10] 李曼菱,章桃,杨桃,等.术前超声联合临床特点构建的列线图对卵巢癌淋巴结转移的预测价值[J].中国妇产科临床杂志,2025,26(1):65-67.
[11] 韩清,史雨冉.血清VEGF、ES及性激素对多囊卵巢综合征患者子宫内膜及卵巢间质血流参数的影响分析[J].中国超声医学杂志,2025,41(1):79-82.
[12] 王丽,李苑瑛,高萍,等.消瘤汤对子宫肌瘤患者血清肿瘤标志物、雌激素及血管内皮生长因子水平的影响[J].中华中医药学刊,2023,41(9):160-162.
[13] YUAN Z M,WANG L H,CHEN C.Prognostic value of serum α-HBDH levels in patients with lung cancer[J].World J Surg Oncol,2023,21(1):78.
[14] 江娜,王秀虹,程欣.YAP1、miR-31与老年卵巢癌患者微血管密度的关系[J].中国老年学杂志,2022,42(1):37-40.
[15] AHMAD A,NAWAZ M I.Molecular mechanism of VEGF and its role in pathological angiogenesis[J].J Cell Biochem,2022,123(12):1938-1965.
[16] 孙丽莎,邓红玉,沈浩明,等.SP1介导CD147通过HIF-1α/VEGF信号通路影响卵巢癌的血管形成[J].重庆医科大学学报,2021,46(6):649-654.
[17] DUDLEY A C,GRIFFIOEN A W.Pathological angiogenesis:Mechanisms and therapeutic strategies[J].Angiogenesis,2023,26(3):313-347.
[18] LEONE R D,POWELL J D.Metabolism of immune cells in cancer[J].Nat Rev Cancer,2020,20(9):516-531.
[19] BIRTS C N,BANERJEE A,DARLEY M,et al.p53 is regulated by aerobic glycolysis in cancer cells by the CtBP family of NADH-dependent transcriptional regulators[J].Sci Signal,2020,13(630):eaau9529.
[20] MARTÍNEZ-REYES I,CHANDEL N S.Cancer metabolism:Looking forward[J].Nat Rev Cancer,2021,21(10):669-680.
[21] 李艳芹,郑子金,吕晋谊,等.免疫检查点抑制剂联合抗血管生成治疗在卵巢癌中的应用研究进展[J].中国实用妇科与产科杂志,2023,39(6):660-664.
[22] 童露瑶,雷理仪,陈军,等.代谢综合征及其组分与卵巢癌发病风险的关系[J].实用医学杂志,2022,38(10):1280-1285.
[23] 楼华,魏晓,周东晨,等.瘦素受体与高级别浆液性卵巢癌转移的生物信息学相关性[J].现代妇产科进展,2021,30(4):251-254.
[24] 白永颖,朱波,朱宇宁,等.血清α-羟基丁酸脱氢酶表达水平在卵巢癌辅助诊断中的应用[J].中华检验医学杂志,2019,42(7):529-534.
[25] ATALLAH G A,ABD AZIZ N H,TEIK C K,et al.New predictive biomarkers for ovarian cancer[J].Diagnostics(Basel),2021,11(3):465.